In fact, FBXO22 does not affect the proliferation of renal cancer cells; however, FBXO22 restricts the invasion and migration of renal cancer cells by abolishing epithelial‐mesenchymal transition (EMT) and increasing the activity of tissue inhibitor of matrix metalloproteinase‐1 (TIMP‐1), leading to the suppression of MMP‐9 expression and activity. Here, FBXO22 is linked to renal carcinoma.